April 15, 2026 09:49 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'ECI deviated from Bihar procedure': Supreme Court raises concerns over voter deletion in Bengal SIR | Noida workers’ protest turns violent: Stones pelted, vehicles damaged over wage hike demand | Oil prices jump above $103 a barrel as US moves to block Iran-linked shipping | I don’t care if they come back or not, says Trump after Iran talks collapse | Legendary singer Asha Bhosle suffers cardiac arrest, hospitalised | Big boost to India–Mauritius ties: S. Jaishankar hands over 90 e-buses | Middle East tension: Iranian delegation arrives in Islamabad for major talks, 10,000 security personnel deployed | Ranveer Singh visits RSS HQ amid Dhurandhar 2 success, triggers speculation | ED raids ex-Bengal minister Partha Chatterjee; SSC scam resurfaces ahead of polls | Amit Shah promises UCC, ₹3,000 aid per month for women and youth in BJP’s Bengal manifesto
UK | COVID booster vaccine

UK approves COVID-19 booster vaccine for people over 40 years

| @indiablooms | Nov 16, 2021, at 01:32 am

London/UNI/Sputnik: The United Kingdom’s Joint Committee on Vaccination and Immunisation (JCVI) on Monday announced that people over 40 years old living in the country will now be eligible to receive a booster COVID-19 vaccine six months after having their second dose, as a new study showed that boosters give over 90 percent protection in adults over 50.

“JCVI has previously advised booster vaccination for all adults aged 50 years and over and those in a Covid-19 at-risk group. The offer has now been broadened to include those aged 40 to 49 years,” the committee said in a statement.

The booster vaccines to be offered to this new age group are Pfizer-BioNTech and Moderna, the same mRNA-type vaccine that has been used since September in people over 50 and at higher risk from the coronavirus SARS-CoV-2.

So far, more than 12,6 million people in the UK have had the third dose.

According to a study released on Monday by the UK Health Security Agency, two weeks after receiving a booster dose, protection against symptomatic infection in adults aged 50 years and over was 93.1 percent in those who first had AstraZeneca as their primary vaccine and 94.0 percent for Pfizer-BioNTech.

The JCVI also advised that all 16- to 17-year-olds who are not in an at-risk group should be offered a second dose of the Pfizer vaccine 12 weeks or more following the first vaccine dose.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.